Cornelis Jh van de Velde

Summary

Affiliation: Leiden University Medical Center
Country: The Netherlands

Publications

  1. pmc Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study
    I D Nagtegaal
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    BMC Cancer 1:7. 2001
  2. ncbi request reprint Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902
    J A van der Hage
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 19:4224-37. 2001
  3. ncbi request reprint Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854
    J A van der Hage
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    Eur J Cancer 37:2184-93. 2001
  4. ncbi request reprint Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get!
    L Duchateau
    EORTC, Brussels, Belgium
    Biometrics 56:886-92. 2000
  5. ncbi request reprint The role of meta-analyses in assessing cancer treatments
    R Sylvester
    European Organization for Research and Treatment of Cancer EORTC Data Center, Avenue E Mounier 83, Bte 11, 1200, Brussels, Belgium
    Eur J Cancer 36:1351-8. 2000
  6. ncbi request reprint Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
    L Biganzoli
    Investigational Drug Branch for Breast Cancer, European Organization for the Research and Treatment of Cancer Data Center, and Jules Bordet Institute, Brussels, Belgium
    J Clin Oncol 20:3114-21. 2002
  7. doi request reprint Validation of prognostic indices using the frailty model
    C Legrand
    European Organisation for Research and Treatment of Cancer, 1200, Brussels, Belgium
    Lifetime Data Anal 15:59-78. 2009
  8. ncbi request reprint Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer
    L Duchateau
    European Organization for Research and Treatment of Cancer EORTC, Brussels, Belgium
    Control Clin Trials 22:538-47. 2001
  9. ncbi request reprint Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences
    M A Nooij
    Department of Clinical Oncology, Leiden University Medical Centre, Albinusdreef 2, The Netherlands
    Eur J Cancer 39:614-21. 2003
  10. ncbi request reprint Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853
    N Bijker
    Departments of Radiation Oncology and Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 19:2263-71. 2001

Collaborators

Detail Information

Publications15

  1. pmc Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study
    I D Nagtegaal
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    BMC Cancer 1:7. 2001
    ..Data concerning involvement of individual cell types are readily available but little is known about the coordinate interactions between both forms of immune response...
  2. ncbi request reprint Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902
    J A van der Hage
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 19:4224-37. 2001
    ....
  3. ncbi request reprint Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854
    J A van der Hage
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    Eur J Cancer 37:2184-93. 2001
    ..65). One course of perioperative polychemotherapy does improve PFS and locoregional control in early stage breast cancers. This effect is still present after 11 years of follow-up...
  4. ncbi request reprint Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get!
    L Duchateau
    EORTC, Brussels, Belgium
    Biometrics 56:886-92. 2000
    ....
  5. ncbi request reprint The role of meta-analyses in assessing cancer treatments
    R Sylvester
    European Organization for Research and Treatment of Cancer EORTC Data Center, Avenue E Mounier 83, Bte 11, 1200, Brussels, Belgium
    Eur J Cancer 36:1351-8. 2000
    ....
  6. ncbi request reprint Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
    L Biganzoli
    Investigational Drug Branch for Breast Cancer, European Organization for the Research and Treatment of Cancer Data Center, and Jules Bordet Institute, Brussels, Belgium
    J Clin Oncol 20:3114-21. 2002
    ..To compare the efficacy and tolerability of the combination of doxorubicin and paclitaxel (AT) with a standard doxorubicin and cyclophosphamide (AC) regimen as first-line chemotherapy for metastatic breast cancer...
  7. doi request reprint Validation of prognostic indices using the frailty model
    C Legrand
    European Organisation for Research and Treatment of Cancer, 1200, Brussels, Belgium
    Lifetime Data Anal 15:59-78. 2009
    ..Our approach is applied to a real bladder cancer database for which we demonstrate how to investigate and interpret heterogeneity in prognostic index effect over centers...
  8. ncbi request reprint Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer
    L Duchateau
    European Organization for Research and Treatment of Cancer EORTC, Brussels, Belgium
    Control Clin Trials 22:538-47. 2001
    ..Mortality can change substantially with follow-up time. The absolute survival differences in the case study, for instance, increase from 2.6% at 2 years to 5.6% at 5 years...
  9. ncbi request reprint Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences
    M A Nooij
    Department of Clinical Oncology, Leiden University Medical Centre, Albinusdreef 2, The Netherlands
    Eur J Cancer 39:614-21. 2003
    ..Based on these data, an interruption of chemotherapy (CMF), if this is the wish of the patient, is justified...
  10. ncbi request reprint Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853
    N Bijker
    Departments of Radiation Oncology and Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 19:2263-71. 2001
    ..Margin status is the most important factor in the success of BCT for DCIS; additionally, young age and symptomatic detection of DCIS have negative prognostic value...
  11. ncbi request reprint Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS
    N Bijker
    Department of Pathology, The Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Amsterdam, The Netherlands
    Eur J Surg Oncol 27:135-40. 2001
    ..The risk of local recurrence in itself, and hence the success of BCT for DCIS, may however be influenced by the quality of the initial procedures that were conducted...
  12. ncbi request reprint Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials
    J G Klijn
    Dr Daniel den Hoed Kliniek and University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 19:343-53. 2001
    ..Therefore, if a premenopausal woman with advanced breast cancer is thought to be suitable for endocrine treatment, it is proposed that the combination of a LHRH agonist plus tamoxifen be considered as the new standard treatment...
  13. ncbi request reprint Treatment outcome studies. pitfalls in current methods and practice
    C Legrand
    European Organization for Research and Treatment of Cancer, Av E Mounier 83, Box 11, B 1200 Brussels, Belgium
    Eur J Cancer 38:1173-80. 2002
    ..Most of the studies use registry data, while only a few use discharge data or data available from clinical trials...
  14. pmc Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ
    N Bijker
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands
    Br J Cancer 84:539-44. 2001
    ....
  15. ncbi request reprint Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
    R Paridaens
    Universitair Ziekenhuis, Gasthuisberg, Leuven, Belgium
    Ann Oncol 14:1391-8. 2003
    ..We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women...